ban on compounded semaglutide FDA issues warning about some versions of for diabetes, weight loss FDA Ban on Compounded GLP-1

The median duration of GLP-1RA use was 21 months (IQR: 1531), and the median duration of insulin use was 23 months (IQR: 1538)

In a December report on its website, the FDA said some compounders were using salt forms of semaglutide in their agents, which are different from the ingredients used in Novo Nordisks FDA-approved versions of the drug

Semaglutide works by slowing stomach emptying and signaling fullness to your brainbut this mechanism often causes temporary nausea, vomiting, or constipation during the initial adjustment phase

Despite improved glucose control, insulin levels often decreased during Retatrutide treatment